The oral tyrosine kinase inhibitors (TKI) dasatinib, imatinib, ponatinib, nilotinib and bosutinib each target BCR-ABL, yet are structurally distinct from one another.^[@bib1],\ [@bib2],\ [@bib3],\ [@bib4],\ [@bib5],\ [@bib6]^ The selection of BCR-ABL TKI treatment for an individual patient is influenced by factors including any previous treatment, likelihood of benefit, risk of toxicities and the potential for end-organ damage resulting from use, particularly as a long-term therapy is expected in chronic myeloid leukemia in chronic phase (CML-CP). Despite considerable overlap of safety profiles, there are distinct drug-specific adverse events associated with each TKI.^[@bib2]^

Peripheral arterial disease (PAD) is often associated with claudication, and may result in critical limb ischemia, and increased risks of loss of limb or death.^[@bib7]^ We evaluated safety databases of dasatinib clinical trials in patients with Philadelphia chromosome-positive (Ph+) leukemias to identify PAD or PAD-related events. We also conducted a standardized incidence ratio (SIR) analysis to evaluate the rate of PAD or PAD-related events in the trials relative to the rate in external reference populations derived from administrative data sets, representing a general adult population in the United States and a CML population that did not receive dasatinib. This retrospective analysis used pooled safety data from 2712 adults with CML or Ph+ acute lymphoblastic leukemia (ALL) treated with dasatinib in 11 clinical trials, including two first-line trials (*n*=324) and nine trials in imatinib-resistant or -intolerant patients (*n*=2388; [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). The median duration of dasatinib treatment was 19 months (range: 0.03--93 months). The trial enrollment criteria permitted inclusion of patients with myocardial infarction \>6 months prior, congestive heart failure \>3 months prior and previously uncontrolled angina controlled ⩾3 months.

Bristol-Myers Squibb safety databases for the included trials were examined to identify PAD or PAD-related events, using the following Medical Dictionary for Regulatory Activities preferred terms: arterial stenosis, arterial thrombosis, arteriosclerosis, arterial stenosis limb, intermittent claudication, femoral artery occlusion, necrosis ischemic and PAD.

For the SIR analysis (SIR=observed number of events/expected number of events; detailed description in [Supplementary Materials](#sup1){ref-type="supplementary-material"}), two external populations were extracted from Truven Health Analytics Marketscan Commercial Claims and Medicare [Supplementary database](#sup1){ref-type="supplementary-material"} (Ann Arbor, MI, USA) between 2008 and 2013. MarketScan consists of data from commercial health plans, Medicaid, Medicare, and self-insurance for Americans. Each reference population included individuals enrolled in the databases for ⩾60 days before the index date. Adult patients were included in the general reference population (*n*=90 000 000), and the CML reference population had ⩾2 diagnostic codes for CML and were not using dasatinib (*n*=15 000). To obtain the expected number of cases, the age and gender-specific person-time of dasatinib-treated patients in the trials were multiplied by the age and gender-specific rates of events in the external populations.

PAD or PAD-related events were detected in 11 patients during dasatinib treatment among 2712 individuals with a cumulative dasatinib exposure of 6421 patient-years, which corresponds to a cumulative incidence of 0.4% and an incidence rate (per 100 patient-years) of 0.2%. Of the 11 patients, all were previously treated with a TKI; 8 were resistant and 3 were intolerant to prior imatinib therapy ([Table 1](#tbl1){ref-type="table"}). No cases of PAD or PAD-related events were identified among the 258 patients treated with first-line dasatinib in DASatinib versus Imatinib Study In treatment-Naive CML patients (DASISION) (median duration of 60 months (range: 0.03--73 months)). Characteristics, comorbidities and risk factors of the 11 patients with PAD or a PAD-related event are shown in [Table 1](#tbl1){ref-type="table"}. For these patients, median age at baseline was 68 years (range: 44--80 years) and median duration of dasatinib before diagnosis of PAD or PAD-related event was 777 days (range: 3--2227 days). Median duration of prior imatinib therapy amongst these patients was 29 months (*n*=9; range: 2--74 months). Of the 11 patients, 8 had CML-CP, 2 had CML in accelerated phase (CML-AP) and one had CML in blast phase (CML-BP) of lymphoid phenotype. Ten of the 11 patients were on BID (twice daily) dosing regimens. Of the eight patients with CML-CP, only one started at a dose of 100 mg QD (once daily), the current recommended dose of dasatinib for CML-CP.^[@bib2]^ Dosing regimens for the other seven patients with CML-CP ranged from 25 to 70 mg BID. The current recommended dose for CML-AP or CML-BP is 140 mg QD;^[@bib2]^ however, the patients with CML-AP (*n*=2) and CML-BP (*n*=1) received a 70 mg BID starting dose of dasatinib.

All 11 patients had pre-existing comorbidities/conditions that potentially increased the risk of developing PAD ([Table 1](#tbl1){ref-type="table"}), including one patient who had prior arterial bypass surgery, one with a history of angioplasty and stent, and one who had pre-existing PAD. Furthermore, six patients had hypertension, four had pre-existing ischemic heart disease, four were former or current smokers, two had pre-existing noncardiac atherosclerosis, two had hypercholesterolemia, two had diabetes mellitus and one had deep vein thrombosis (DVT). Of nine patients with PAD or a PAD-related event with available data, all were receiving other medications at baseline. The PAD or PAD-related events in the 11 cases included intermittent claudication (four patients), femoral artery occlusion (two patients), PAD (two patients), peripheral ischemia (two patients), peripheral artery thrombosis (one patients) and peripheral vascular disorder (one patient), with one patient experiencing two of these events ([Table 1](#tbl1){ref-type="table"}). All events identified were Common Terminology Criteria grade ⩽3. Of seven patients with available molecular response data, best responses at any time included 27% (*n*=3) with a major molecular response, 18% (*n*=2) achieving complete molecular response (CMR~4.5~) and 36% (*n*=4) achieving a complete cytogenetic response. Dasatinib treatment was interrupted in five patients due to PAD or a PAD-related event, and no patients discontinued dasatinib because of PAD or PAD-related events ([Table 1](#tbl1){ref-type="table"}).

SIR analysis showed that the observed number of PAD or PAD-related events (*n*=11) in the pooled population did not exceed the expected number of events (*n*=20) in the general population (SIR (95% confidence interval; CI), 0.56 (0.31--1.01)). Similarly, the observed number of PAD or PAD-related events (*n*=11) in the pooled population did not exceed the expected number (*n*=43) based on rates in the reference CML population (SIR (95% CI), 0.26 (0.14--0.46); [Supplementary Table S2](#sup1){ref-type="supplementary-material"}).

The current analysis investigated the incidence of PAD or PAD-related events in patients treated with dasatinib to test the hypothesis that PAD might be a class effect among second- and third-generation BCR-ABL TKIs. Previous reports have described an association of PAD with either ponatinib or nilotinib treatment.^[@bib4],\ [@bib5]^ The cumulative incidence and incidence rate (per 100 patient-years) reported here are higher than those previously published in a retrospective analysis by Giles and colleagues for imatinib (0.2% and 0.1%, respectively); however, they are lower than cited for nilotinib (1.3% and 0.5%, respectively) and interferon-α plus cytarabine (0.6% and 0.6%, respectively; [Table 2](#tbl2){ref-type="table"}).^[@bib8]^ No PAD or PAD-related events were identified in newly diagnosed CML patients treated with dasatinib in the DASISION trial, which has the longest median exposure time to dasatinib of any study.

Generally, risk factors for cardiovascular disease are also risk factors for PAD or PAD-related events.^[@bib7],\ [@bib9]^ The prevalence of PAD increases with age and concomitant cardiovascular disease risk factors.^[@bib8],\ [@bib10]^ Some clinical trials report a lower incidence of PAD in CML and Ph+ ALL compared with published rates for the general population; however, this may be affected by the study entry criteria that exclude patients with significant cardiovascular disease.^[@bib7],\ [@bib8],\ [@bib9],\ [@bib11]^ The included dasatinib clinical trials (with the exception of CA180-002) allowed the participation of patients with diabetes and patients with a history of cardiac comorbidities. Ten of the 11 patients with PAD or PAD-related events had at least one potential risk factor for PAD (the remaining patient had DVT).

The extended survival of CML patients in the TKI era makes it important to understand the implications of long-term treatment and understand better the potentially irreversible and severe toxicities of some TKIs. The results presented here do not show an association between dasatinib treatment and development of symptomatic PAD in patients with CML or Ph+ ALL, and are consistent with the hypothesis that PAD observed in CML patients is not a class effect of second- and third-generation BCR-ABL TKIs. Similar analyses evaluating cardiac and cerebrovascular adverse events in CML patients treated with BCR-ABL TKIs are warranted, based on the findings by Chai-Adisaksopha *et al.*^[@bib12]^ Second-generation TKIs, including dasatinib, have established higher rates of molecular remission in CML than reported with imatinib, with the hope for cure or at least treatment-free remissions. When selecting treatment for Ph+ leukemia, physicians should carefully assess overall cardiovascular health, as well as pre-existing comorbidities and risk factors present at baseline.
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###### 

Click here for additional data file.

###### Characteristics, outcomes, risk factors and management of PAD and PAD-related adverse events

  *Age/CML phase*                                 *Pre-existing comorbidities and risk factors present at baseline*                           *Adverse event characteristics*              *Outcomes (best response at any time)*    *Adverse event management*                                             
  ---------------------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------------- ---------------------------------------- ---------------------------- ------------------ ----- ----- ----- ----- ------------------
  73/CP                                                      Pre-existing heart disease, previous smoker                                          Femoral artery occlusion                 1                                           25 mg BID, 5 d per wk     2227                Yes   NR    NR    No      Interrupted
  68/AP                                                                    Previous smoker                                                       Intermittent claudication                 2, 2                                              70 mg BID           NR, 42              Yes   Yes   Yes   Yes         None
  80/AP[b](#t1-fn3){ref-type="fn"}           Pre-existing noncardiac atherosclerosis, hypertension, hypercholesterolemia                          Femoral artery occlusion                 2                                                 70 mg BID           3                   No    No    No    No      Interrupted
  63/CP                                                                   Diabetes mellitus                                                                 PAD                            1, 3                                              70 mg BID           343, 657            Yes   No    No    No          None
  74/CP                                          Pre-existing ischemic heart disease, hypertension, diabetes mellitus                            Intermittent claudication                 2                                                 70 mg BID           868                 Yes   No    No    No          None
  71/CP                                                                      Hypertension                                                       Peripheral artery thrombosis               3, 3                                              50 mg BID           777, 870            Yes   Yes   No    Yes     Interrupted
  54/LBP                                                                 Deep vein thrombosis                                                    Intermittent claudication                 2                                                 70 mg BID           151                 Yes   NR    NR    Yes         None
  67/CP[c](#t1-fn4){ref-type="fn"}    Pre-existing ischemic heart disease, pre-existing noncardiac atherosclerosis, hypertension                            PAD                            3                                                 70 mg BID           367                 Yes   NR    NR    No          None
  75/CP                                              Arterial bypass surgery, pre-existing ischemic heart disease                  Intermittent claudication Peripheral vascular disorder  1 3                                               50 mg BID           1177 1323           Yes   NR    NR    No    None Interrupted
  65/CP                                              PAD on a pre-existing lesion, hypertension, previous smoker                                    Peripheral ischemia                    3, 3, 3                                           100 mg QD           1229, 1361, 1447    Yes   No    No    No          None
  44/CP                                      History of angioplasty and stent, hypertension, hypercholesterolemia, smoker                           Peripheral ischemia                    3                                                 50 mg BID           1692                Yes   Yes   Yes   Yes     Interrupted

Abbreviations: AP, accelerated phase; BID, twice daily; CCyR, complete cytogenetic response; CML, chronic myeloid leukemia; CMR, complete molecular response; CP, chronic phase; CTC, Common Terminology Criteria; d, day; LBP, lymphoid blast phase; MMR, major molecular response; NR, not reported; PAD, peripheral arterial disease; QD, once daily; wk, week.

National Cancer Institute CTCAE v.3.0.

This patient was the sole patient for whom the PAD-related adverse event was not a first occurrence.

The chronic phase disease of this patient had clonal evolution.

###### Incidence of PAD and PAD-related events in patients receiving treatment for Ph+ leukemia in clinical trials

                                               *Dasatinib*                                      *Imatinib*        *Nilotinib*                                                                  *No BCR-ABL inhibitor*
  -------------------------------------------- ----------------------------------------- ------------------------ ------------------------------------------------ ------------------------------------------------------------------------------
  Dose                                         15--240 mg per day                            400 mg QD or BID     300 or 400 mg BID                                 IFN 5 × 10^6^ U/m^2^ per day; Ara-C 20 mg/m^2^ per day for 10 days per month
  Trial                                        11 dasatinib trials                         TOPS, IRIS, ENESTnd    ENESTnd                                                                               IRIS
  Study population                             Ph+ leukemia[a](#t2-fn2){ref-type="fn"}    Newly diagnosed CML-CP  Newly diagnosed CML-CP                                                       Newly diagnosed CML-CP
  Patients treated (*n*)                       2712                                                1301           556                                                                                   533
  PAD cases[b](#t2-fn3){ref-type="fn"} (*n*)   11                                                   2             7                                                                                      3
  Cumulative incidence (%)                     0.4                                                 0.2            1.3                                                                                   0.6
  Exposure, patient-years                      6421                                                4523           1464                                                                     534[c](#t2-fn4){ref-type="fn"}
  Incidence rate (per 100 patient-years), %    0.2                                                 0.1            0.5                                                                                   0.6
  Data source                                  Current analysis                                                   Adapted from Giles *et al.*^[@bib7],\ [@bib8]^   

Abbreviations: Ara-C, cytarabine; BID, twice daily; CML, chronic myeloid leukemia; CP, chronic phase; ENESTnd, Evaluating Nilotinib Efficacy and Safety in clinical Trials-newly diagnosed patients; IFN, interferon; IRIS, International Randomized Study of Interferon and ST1571; PAD, peripheral arterial disease; Ph+, Philadelphia chromosome-positive; QD, once daily; TOPS, Tyrosine Kinase Inhibitor Optimization and Selectivity Study.

Includes newly diagnosed CML-CP (*n*=324) and imatinib-resistant or -intolerant CML (any phase) and Ph+ ALL (*n*=2388).

In Giles *et al*,^[@bib7]^ PAD included atherosclerotic and thrombotic events, excluding functional (vasoreactive), embolic or aneurysmal disorders, in the arteries of lower and upper extremities. Terms indicative of PAD included: arterial disorder, peripheral ischemia, arterial insufficiency, arteriosclerosis obliterans, peripheral vascular disorder, arterial occlusive disease, femoral arterial stenosis, arterial stenosis, femoral artery occlusion, peripheral artery angioplasty, arterial stenosis limb, intermittent claudication, peripheral revascularization, arterial thrombosis limb and PAD.^[@bib8]^

Patients treated with IFN+Ara-C had shorter median duration of therapy (8 months) compared with nilotinib (36 months) and imatinib (45 months) cohorts, because of early crossover to imatinib.
